Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
0.1528
Dollar change
-0.0119
Percentage change
-7.23
%
Index- P/E- EPS (ttm)-47.12 Insider Own0.06% Shs Outstand9.42M Perf Week-9.10%
Market Cap1.44M Forward P/E- EPS next Y-1.17 Insider Trans0.00% Shs Float9.42M Perf Month-56.21%
Income-24.95M PEG- EPS next Q-0.57 Inst Own20.85% Short Float0.14% Perf Quarter-48.22%
Sales0.00M P/S- EPS this Y-94.84% Inst Trans- Short Ratio0.00 Perf Half Y-95.31%
Book/sh1.09 P/B0.14 EPS next Y60.61% ROA-115.20% Short Interest0.01M Perf Year-98.95%
Cash/sh0.86 P/C0.18 EPS next 5Y- ROE-243.74% 52W Range0.14 - 21.56 Perf YTD-98.08%
Dividend Est.- P/FCF- EPS past 5Y46.80% ROI-263.01% 52W High-99.29% Beta5.14
Dividend TTM- Quick Ratio1.77 Sales past 5Y-17.88% Gross Margin- 52W Low8.37% ATR (14)0.03
Dividend Ex-Date- Current Ratio1.77 EPS Y/Y TTM64.90% Oper. Margin0.00% RSI (14)24.95 Volatility8.56% 14.30%
Employees40 Debt/Eq1.13 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price8.00
Option/ShortNo / Yes LT Debt/Eq1.13 EPS Q/Q96.90% Payout- Rel Volume0.12 Prev Close0.16
Sales Surprise- EPS Surprise13.47% Sales Q/Q- EarningsAug 08 BMO Avg Volume6.39M Price0.15
SMA20-26.76% SMA50-51.32% SMA200-94.21% Trades Volume749,038 Change-7.23%
Date Action Analyst Rating Change Price Target Change
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Sep-18-24 04:05PM
Sep-16-24 08:05PM
08:20AM
08:05AM
Sep-13-24 08:20AM
08:05AM Loading…
08:05AM
Aug-13-24 08:05AM
Aug-08-24 08:05AM
Jul-01-24 04:20PM
Jun-28-24 09:20AM
Jun-17-24 07:40AM
Jun-03-24 08:05AM
May-14-24 08:05AM
May-08-24 12:54PM
08:05AM
07:37AM Loading…
May-02-24 07:37AM
Apr-16-24 12:47PM
Apr-15-24 04:05PM
Apr-11-24 08:15AM
08:00AM
Apr-10-24 09:00AM
Mar-18-24 06:00AM
Mar-07-24 08:55AM
Mar-05-24 01:51PM
08:05AM
Mar-04-24 09:00AM
Nov-14-23 08:05AM
Nov-01-23 07:45AM
Aug-10-23 08:05AM
Aug-06-23 07:14AM
06:40PM Loading…
Aug-04-23 06:40PM
Aug-01-23 10:15PM
Jul-30-23 02:17PM
Jul-18-23 08:05AM
May-11-23 08:05AM
Apr-01-23 08:51AM
Mar-30-23 07:45AM
07:30AM
Mar-29-23 10:13AM
Mar-03-23 06:57PM
Feb-13-23 08:05AM
Jan-09-23 08:05AM
Dec-12-22 09:54AM
07:35AM
Nov-10-22 08:05AM
Nov-09-22 08:05AM
Nov-03-22 09:06AM
Sep-19-22 08:45AM
Aug-11-22 08:05AM
Jun-09-22 08:05AM
May-12-22 08:05AM
Apr-12-22 08:05AM
Mar-29-22 08:05AM
Mar-24-22 08:05AM
Feb-09-22 08:05AM
Jan-21-22 08:05AM
Dec-15-21 08:05AM
Dec-10-21 05:38PM
Nov-23-21 08:05AM
07:59AM
Nov-15-21 08:05AM
Nov-12-21 08:05AM
Nov-11-21 04:45PM
08:30AM
Nov-02-21 09:00AM
Oct-27-21 08:05AM
Oct-26-21 08:05AM
Sep-28-21 08:05AM
Aug-17-21 08:05AM
Aug-12-21 08:05AM
Jul-16-21 08:05AM
Jun-29-21 08:05AM
May-27-21 09:00AM
May-26-21 09:32AM
09:00AM
May-17-21 06:00AM
May-11-21 09:00AM
Apr-09-21 09:00AM
Mar-31-21 08:00AM
Feb-09-21 07:30PM
Jan-11-21 08:00AM
Jan-06-21 12:00PM
Dec-19-20 01:45PM
Dec-02-20 08:00AM
Nov-20-20 07:37AM
Nov-19-20 04:15PM
Nov-16-20 08:00AM
Nov-10-20 08:40AM
Nov-09-20 09:00AM
06:00AM
Nov-08-20 11:15PM
Nov-03-20 09:00AM
Sep-01-20 09:00AM
Aug-14-20 09:00AM
Aug-06-20 09:00AM
Jul-21-20 09:00AM
Jun-30-20 12:00PM
11:30AM
Jun-29-20 09:00AM
Jun-25-20 09:00AM
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.